Elthera has a very experienced management and antibody development team with a proven track record in bringing compounds from research into clinical studies and to market (e.g. Lucentis, Avastin) as well as strong advisor network in all relevant corporate functions


Dr. Anne Schmidt, CEO, co-founder

Anne is an experienced executive with 18 years of experience in different management positions in Biotech and pharma companies, most recently at ESBATech / Novartis. Anne has experience working in small and large pharma environment in the development of diagnostics and vaccines and a track record of successfully bringing antibody based products from the research stage to the clinical proof of concept, with four projects resulting in a positive proof of concept. She holds a PhD in Immunology from University of Stuttgart and worked during her time in academia at the German Cancer Research Center on tumor immunology and later on at the University of Erlangen.


Dr. Gunther Spohn, CSO, co-founder

Gunther has more than 15 years of experience in different management positions in the Biotechnology and pharmaceutical industry and a track record as a leader of early drug development projects in the field of therapeutic antibodies and vaccines.  He has expert knowledge in the pharmacological characterization of antibodies and the development of bioanalytical methods for preclinical and clinical studies and extensive expertise in diverse aspects of drug development such as preclinical efficacy and safety testing, process development, patenting, regulatory filings. He holds a PhD in Microbiology from the University of Würzburg.


Dr. Jacques Gaudreault, COO, co-founder

Jacques has more than 20 years of experience in the pharmaceutical industry and has worked as a preclinical and clinical pharmacologist, Project Leader, and Discovery Unit Head.  He has been involved in the development and approval of several biologics, including Avastin (an anti-VEGF antibody for treatment of several tumor types), as well as Lucentis (an antibody for the treatment of Age Related Macular Degeneration). He holds a PhD in Pharmaceutics from the University of Montreal and a BSC in Pharmacy.